Other Events ·
Roivant reports brepocitinib met primary endpoint in Phase 3 NIU trials, plans sNDA filing in H1 2027
ROIVRoivant Sciences Ltd.
Roivant Sciences announced that its subsidiary Priovant achieved positive results from the CLARITY program evaluating brepocitinib for non-infectious uveitis. The drug met the primary endpoint of time to treatment failure and showed statistically significant benefits across all key secondary endpoints in two Phase 3 trials, including sustained steroid-free quiescence and resolution of macular edema compared with placebo. Priovant intends to file a supplemental New Drug Application for brepocitinib in the first half of calendar year 2027. Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that develops and commercializes medicines through nimble subsidiaries.